The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone973-290-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.14 million
Profitability
Miscellaneous
Employees62
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
The Medicines (NASDAQ:MDCO) Frequently Asked Questions
What is The Medicines' stock symbol?
The Medicines trades on the NASDAQ under the ticker symbol "MDCO."
How were The Medicines' earnings last quarter?
The Medicines Company (NASDAQ:MDCO) announced its earnings results on Wednesday, July, 24th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.73) by $0.02. During the same quarter last year, the business posted ($0.63) EPS. View The Medicines' Earnings History.
When is The Medicines' next earnings date?
What price target have analysts set for MDCO?
14 brokers have issued twelve-month price objectives for The Medicines' shares. Their predictions range from $48.00 to $145.00. On average, they anticipate The Medicines' stock price to reach $73.33 in the next year. This suggests a possible upside of 38.1% from the stock's current price. View Analyst Price Targets for The Medicines.
What is the consensus analysts' recommendation for The Medicines?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.
Has The Medicines been receiving favorable news coverage?
News headlines about MDCO stock have been trending somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. The Medicines earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for The Medicines.
Are investors shorting The Medicines?
The Medicines saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 24,350,000 shares, an increase of 5.6% from the August 30th total of 23,050,000 shares. Based on an average daily trading volume, of 2,080,000 shares, the short-interest ratio is currently 11.7 days. Currently, 32.2% of the shares of the company are short sold. View The Medicines' Current Options Chain.
Who are some of The Medicines' key competitors?
Some companies that are related to The Medicines include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC) and Perrigo (PRGO).
What other stocks do shareholders of The Medicines own?
Who are The Medicines' key executives?
The Medicines' management team includes the folowing people:
- Mr. Mark Timney, CEO & Director (Age 54)
- Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
- Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
- Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
- Dr. Goutham Krishna Gorti, VP & Head of Investor Relations
Who are The Medicines' major shareholders?
The Medicines' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.02%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.
Which institutional investors are buying The Medicines stock?
MDCO stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox, Fredric N Eshelman and Mark Timney. View Insider Buying and Selling for The Medicines.
How do I buy shares of The Medicines?
Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is The Medicines' stock price today?
One share of MDCO stock can currently be purchased for approximately $53.09.
How big of a company is The Medicines?
The Medicines has a market capitalization of $4.21 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.
What is The Medicines' official website?
How can I contact The Medicines?
The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]
MarketBeat Community Rating for The Medicines (NASDAQ MDCO)
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
